Authorities in China have given a green light to an early clinical trial testing inhaled rentosertib for IPF in patients and ...

A constant stream of news, misinformation, and division led columnist Sam Kirton to find ways to reduce the noise — and, in turn, his stress.

Twice a year, columnist Kylene Henderson and her husband, Donnie, make the trek to St. Louis for Donnie's medical ...

Enrollment finished ahead of schedule in a Phase 2 trial testing Calluna Pharma’s experimental CAL101 therapy in adults with ...

Columnist Sam Kirton writes about the passing of a friend with whom he shared a diagnosis of IPF, and reflects on his own patient journey.

A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...